Clinical Trials Browser

INDUSTRY × belantamab mafodotin × Plasma cell × Clear all

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04162210 2026-02-11

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT05714839 2026-01-23

DREAMM-20

Phase 1/2 Recruiting

153 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06679101 2026-01-08

DREAMM-10

Phase 3 Recruiting

520 enrolled

Plasma cell

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04398680 2025-12-04

DREAMM 13

Phase 1 Withdrawn

Plasma cell

Multiple Myeloma, Recurrence

NCT04091126 2025-11-28

DREAMM 9

Phase 1 Active not recruiting

118 enrolled

Plasma cell

Multiple Myeloma

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Not yet recruiting

200 enrolled

Plasma cell

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

Phase 2 Active not recruiting

208 enrolled

Plasma cell

Multiple Myeloma

NCT07217119 2025-10-15

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

Phase 1/2 Active not recruiting

25 enrolled

Plasma cell

Multiple Myeloma

NCT05064358 2025-10-07

DREAMM 14

Phase 2 Active not recruiting

177 enrolled 37 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Phase 1/2 Active not recruiting

14 enrolled

Plasma cell

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Plasma cell

Multiple Myeloma

NCT07084896 2025-07-25

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Phase 1/2 Active not recruiting

106 enrolled

Plasma cell

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT04398745 2025-05-23

DREAMM12

Phase 1 Active not recruiting

36 enrolled

GenitourinaryPlasma cell

Kidney Failure, Chronic, Multiple Myeloma, Renal Insufficiency

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT04177823 2025-03-20

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 Completed

6 enrolled 48 charts

Plasma cell

Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Plasma cell

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03763370 2024-10-15

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

Available

Plasma cell

Multiple Myeloma

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Plasma cell

Multiple Myeloma

NCT06160609 2024-03-12

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Phase 1/2 Terminated

9 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT04549363 2023-12-13

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Phase 3 Terminated

16 enrolled 7 charts

Plasma cell

Multiple Myeloma

NCT02064387 2020-08-11

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Phase 1 Completed

79 enrolled 59 charts

Plasma cell

Multiple Myeloma

Clinical Trials

ALANIS

DREAMM-3

DREAMM-20

DREAMM-10

STOMP

DREAMM 13

DREAMM 9

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

DREAMM5

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

DREAMM 14

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

DREAMM 8

DREAMM12

DREAMM 7

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

DREAMM 6

DREAMM 8

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

DREAMM 7

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

DREAMM 4

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916